Production & Manufacturing

Shilpa Biologicals Pvt. Ltd. (SBPL) has introduced PartnerPower Platform, a proprietary digital transparency solution designed to provide global sponsors with continuous, real-time visibility across biologics development and manufacturing activities. Announced on 22 June 2026 from Dharwad, India, the platform...

Eisai is moving ahead with a major upgrade of its manufacturing facility in Hatfield, Hertfordshire, backed by support from the United Kingdom’s Life Sciences Innovative Manufacturing Fund (LSIMF). The Japanese drugmaker is investing approximately 48 million pounds sterling ($64.5...

Recipharm has unveiled a multi-million-dollar investment in its US operations aimed at increasing sterile fill and finish manufacturing capacity for biologics and advanced therapies. The expansion comes after the company secured a clinical biologics fill and finish agreement with...

MGS, a healthcare-focused contract development and manufacturing organization, has expanded its Hybrid Tooling capability worldwide after successfully deploying the approach alongside its A.i.r. Platform™. The company said the broader rollout is intended to help healthcare manufacturers accelerate product development,...

Chime Biologics and Daewoong Pharmaceutical have entered into a strategic collaboration to develop and manufacture a dupilumab biosimilar candidate referencing Dupixent for global markets. The partnership, announced by VMS Group, combines the development and manufacturing capabilities of Chime Biologics...

Contract research, development, and manufacturing organization (CRDMO) Aragen has announced the successful production of the first commercial-scale GMP batches of Daretabart (hu1418K322A), the lead therapeutic candidate of UK-based Renaissance Pharma Limited. The milestone marks a key step forward in...

Aragen, a global leader in Contract Research, Development, and Manufacturing Organization (CRDMO) services, has announced the successful technology transfer and commercial-scale GMP manufacturing of the first batches of Daretabart, Renaissance Pharma’s lead therapeutic candidate for high-risk neuroblastoma. The milestone...